Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Prostate Specific Membrane Antigen Positive Metastatic Prostate Cancer”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 19 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT07567521
What this trial is testing

TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC

Who this might be right for
Prostate Cancer
C Ray Therapeutics 90
Large-scale testing (Phase 3)Looking for participantsNCT05939414
What this trial is testing

An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.

Who this might be right for
Oligometastatic Prostate Cancer (OMPC)
Novartis Pharmaceuticals 450
Early research (Phase 1)UnknownNCT06237491
What this trial is testing

The Safety and Dosimetry Study of 177Lu-LNC1003 Injection

Who this might be right for
Metastatic Castration-resistant Prostate Cancer, mCRPC
Yantai LNC Biotechnology Singapore PTE. LTD. 12
Not applicableUnknownNCT06201741
What this trial is testing

Evaluate the Human Biodistribution and Dosimetry of the Radionuclide Labeled ZT-111 in Patients With Metastatic Prostate Cancer

Who this might be right for
Prostate Specific Membrane Antigen Positive Metastatic Prostate Cancer
Huashan Hospital 10
Early research (Phase 1)Ended earlyNCT03490838
What this trial is testing

177Lu-PSMA-R2 in Patients With PSMA Positive Progressive, Metastatic, Castration Resistant Prostate Cancer

Who this might be right for
Prostatic Neoplasm
Advanced Accelerator Applications 27
Testing effectiveness (Phase 2)Active Not RecruitingNCT05658003
What this trial is testing

A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals 63
Testing effectiveness (Phase 2)Looking for participantsNCT07226986
What this trial is testing

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC

Who this might be right for
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
Novartis Pharmaceuticals 123
Large-scale testing (Phase 3)Looking for participantsNCT06780670
What this trial is testing

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

Who this might be right for
Prostate Cancer
Novartis Pharmaceuticals 443
Large-scale testing (Phase 3)Looking for participantsNCT07426094
What this trial is testing

PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer

Who this might be right for
Prostate CancerBrachytherapyStereotactic Body Radiation Therapy (SBRT)+2 more
Affidea Nu-med Center of Oncological DIagnostics and Therapy 600
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07310355
What this trial is testing

68Ga-PSMA-0057 and 177Lu-PSMA-0057 in Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer

Who this might be right for
Metastatic Castration-resistant Prostate Cancer (mCRPC)
Chengdu StarRay Therapeutics Co., Ltd 49
Testing effectiveness (Phase 2)Active Not RecruitingNCT06004661
What this trial is testing

Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function

Who this might be right for
Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals 23
Testing effectiveness (Phase 2)Active Not RecruitingNCT07047118
What this trial is testing

JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Who this might be right for
Prostatic Cancer, Castration-Resistant
Novartis Pharmaceuticals 138
Testing effectiveness (Phase 2)Active Not RecruitingNCT06894511
What this trial is testing

An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC

Who this might be right for
Metastatic Castration Resistant Prostate Cancer (mCRPC)
Novartis Pharmaceuticals 7
Testing effectiveness (Phase 2)Enrolling By InvitationNCT05570994
What this trial is testing

177Lu-HTK03170 in mCRPC With PSMA Positive Disease

Who this might be right for
Metastatic Castration-resistant Prostate CancerProstate Cancer MetastaticCastrate Resistant Prostate Cancer
British Columbia Cancer Agency 50
Not applicableLooking for participantsNCT06850545
What this trial is testing

Kuopio Lutetium-177 Study in Patients with PSMA-Positive Metastatic Prostate Cancer

Who this might be right for
Metastatic Prostate AdenocarcinomaPSMA PET-Positive Castration-Resistant Prostate Cancer
Kuopio University Hospital 150
Testing effectiveness (Phase 2)Active Not RecruitingNCT04663997
What this trial is testing

177 LuPSMA-617 vs Docetaxel in Metastatic Castration Resistant and PSMA-Positive Prostate Cancer

Who this might be right for
Prostate Cancer
Canadian Cancer Trials Group 200
Testing effectiveness (Phase 2)Active Not RecruitingNCT06383052
What this trial is testing

177Lu-NYM032 Injection in mCRPC

Who this might be right for
Metastatic Castration-resistant Prostate Cancer
Norroy Bioscience Co., LTD 30
Very early researchStudy completedNCT06359821
What this trial is testing

Evaluate Safety, Whole-Body Distribution and Radiation Dosimetry in Metastatic Castration Resistant Prostate Cancer

Who this might be right for
Metastatic Prostate Cancer
Sichuan University 4
Testing effectiveness (Phase 2)Looking for participantsNCT06972628
What this trial is testing

Treatment of Patients With Progressive mCRPC With 177Lu-PSMA-617

Who this might be right for
Metastatic Castration-Resistant Prostate CancerProstate Cancer Patients With Bone MetastasisProstate Cancer (CRPC)+2 more
Ebrahim S Delpassand 30